Mogamulizumab Treatment Prior to Allogeneic Hematopoietic Stem Cell Transplantation Induces Severe Acute Graft-versus-Host Disease
详细信息 查看全文
- 作者：Takeshi Sugio1 ; Koji Kato1 ; kojikato@intmed1.med.kyushu-u.ac.jp" class="auth_mail" title="E-mail the corresponding author ; Takatoshi Aoki2 ; Takanori Ohta3 ; Noriyuki Saito4 ; Shuro Yoshida4 ; Ichiro Kawano4 ; Hideho Henzan4 ; Masanori Kadowaki5 ; Ken Takase5 ; Tsuyoshi Muta6 ; Kohta Miyawaki1 ; Takuji Yamauchi1 ; Takahiro Shima1 ; Shuichiro Takashima1 ; Yasuo Mori1 ; Goichi Yoshimoto1 ; Kenjiro Kamezaki1 ; Katsuto Takenaka7 ; Hiromi Iwasaki7 ; Ryosuke Ogawa6 ; Yuju Ohno3 ; Tetsuya Eto4 ; Tomohiko Kamimura2 ; Toshihiro Miyamoto1 ; Koichi Akashi1 ; 7
- 关键词：Adult T cell leukemia/lymphoma ; Mogamulizumab ; Allogeneic hematopoietic stem cell transplantation ; Graft-versus-host disease
- 刊名：Biology of Blood and Marrow Transplantation
- 出版年：2016
- 出版时间：September 2016
- 年：2016
- 卷：22
- 期：9
- 页码：1608-1614
- 全文大小：601 K
文摘
- •
MOG improves disease control in patients with ATLL before allo-HSCT.
- •
MOG administration before allo-HSCT increases severe acute GVHD, leading to a high incidence of transplantation-related mortality.
- •
Shorter intervals from the last administration of MOG to allo-HSCT were associated with the development of severe GVHD.